This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 May 2011

Eliquis Receives European Commission Approval

A new oral direct Factor Xa inhibitor has been approved by European Commission for the prevention of venous thromboembolic events.

Eliquis, a new oral direct Factor Xa inhibitor, has received European Commission approval for the prevention of venous thromboembolic events in adult patients who have undergone elective hip or knee replacement surgery.


The approval is based on three clinical trials that showed that, when given orally twice daily, it demonstrated superior efficacy and decreased the risk of bleeding compared to enoxaparin.


Developed in collobaration with Bristol-Myers Squibb and Pfizer, Eliquis, an oral anticoagulant with a 12-to-24-hour post surgery initiation window, helps physicians observe and stabilise post-surgical patients before beginning treatment.


Glostrup Hospital MD Mi

Related News